文献速递肾移植慢性肾脏病肾血管病与高血压

肾移植中的代谢紊乱

Metabolic Disorders with Kidney Transplant.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-04-13

本文综述肾移植候选者和受者中高发的代谢紊乱(糖尿病、甲状旁腺功能亢进、肥胖)及其管理。约60%非糖尿病患者在移植后即刻出现高血糖,7%-30%患者在移植后第一年内发生新发糖尿病;继发性甲状旁腺功能亢进在CKD患者中常见,移植后可持续至66%;肥胖是移植前后最常见的代谢紊乱,与合并症及移植可及性相关。

要点

  • 移植后即刻约60%非糖尿病患者出现高血糖,7%-30%在一年内发生新发糖尿病。
  • 继发性甲状旁腺功能亢进在CKD中常见,移植后可持续至66%,治疗选择包括甲状旁腺切除术和药物管理。
  • 肥胖是移植前后最常见的代谢紊乱,与糖尿病、血脂异常、心血管疾病相关,并影响移植可及性。

核心结论

  • 代谢紊乱在肾移植候选者和受者中高度流行,可 adversely 影响移植后移植物结局。

研究设计与样本

  • 综述,检索范围及答案未在原文中明确报告。

主要发现

  • 约60%非糖尿病患者在移植后即刻出现高血糖。
  • 估计7%-30%患者在移植后第一年内发生新发糖尿病。
  • 继发性甲状旁腺功能亢进在多数CKD患者中存在,移植后可持续至66%,尽管甲状旁腺激素水平 initially 下降。
  • 肥胖是移植前后最常见的代谢紊乱,与糖尿病、血脂异常、心血管疾病相关,并影响移植可及性。

关键数值与推荐

  • 原文未报告具体诊断标准或推荐阈值。

临床怎么用

  • 管理糖尿病、甲状旁腺功能亢进和肥胖可优化移植前后患者状态,并降低手术和心血管并发症风险。
  • 糖尿病管理应优化现有药物方案的风险获益。
  • 继发性甲状旁腺功能亢进治疗选择包括甲状旁腺切除术和药物管理,需考虑患者特异性因素。

局限性

  • 继发性甲状旁腺功能亢进的最佳管理缺乏随机对照试验提供明确推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic disorders are highly prevalent in kidney transplant candidates and recipients and can adversely affect post-transplant graft outcomes. Management of diabetes, hyperparathyroidism, and obesity presents distinct opportunities to optimize patients both before and after transplant as well as the ability to track objective data over time to assess a patient's ability to partner effectively with the health care team and adhere to complex treatment regimens. Optimization of these particular disorders can most dramatically decrease the risk of surgical and cardiovascular complications post-transplant. Approximately 60% of nondiabetic patients experience hyperglycemia in the immediate post-transplant phase. Multiple risk factors have been identified related to development of new onset diabetes after transplant, and it is estimated that upward of 7%-30% of patients will develop new onset diabetes within the first year post-transplant. There are a number of medications studied in the kidney transplant population for diabetes management, and recent data and the risks and benefits of each regimen should be optimized. Secondary hyperparathyroidism occurs in most patients with CKD and can persist after kidney transplant in up to 66% of patients, despite an initial decrease in parathyroid hormone levels. Parathyroidectomy and medical management are the options for treatment of secondary hyperparathyroidism, but there is no randomized, controlled trial providing clear recommendations for optimal management, and patient-specific factors should be considered. Obesity is the most common metabolic disorder affecting the transplant population in both the pre- and post-transplant phases of care. Not only does obesity have associations and interactions with comorbid illnesses, such as diabetes, dyslipidemia, and cardiovascular disease, all of which increase morbidity and mortality post-transplant, but it also is intimately inter-related with access to transplantation for patients with kidney failure. We review these metabolic disorders and their management, including data in patients with kidney transplants.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Cohen E, Korah M, Callender G, et al. Metabolic Disorders with Kidney Transplant. Clin J Am Soc Nephrol. 2020. PMID: 32284323. doi:10.2215/CJN.09310819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。